Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trial
Official title:
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02211027 -
Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA
|
Phase 1 | |
| Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03735628 -
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT03546582 -
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06102447 -
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma
|
N/A | |
| Not yet recruiting |
NCT06295731 -
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
|
Phase 2/Phase 3 | |
| Terminated |
NCT00911326 -
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
| Completed |
NCT04220866 -
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
|
Phase 2 | |
| Withdrawn |
NCT03114280 -
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04849377 -
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
|
Phase 2 | |
| Completed |
NCT03268993 -
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
|
N/A | |
| Recruiting |
NCT04284540 -
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
|
N/A | |
| Recruiting |
NCT04080804 -
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04215978 -
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03746431 -
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05249426 -
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05473156 -
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT02684253 -
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 | |
| Terminated |
NCT03276819 -
A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC
|
N/A |